Understand the source comparison
Growth Hormone Secretagogues Versus Direct IGF-1 Receptor Agonism
Growth hormone secretagogues. Including GHRP-2, MK-677, and hexarelin. Work upstream of IGF-1 by stimulating pituitary GH release or mimicking ghrelin. The resulting GH pulse triggers hepatic IGF-1 secretion within 2–4 hours, which then undergoes normal IGFBP
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Growth hormone secretagogues. Including GHRP-2, MK-677, and hexarelin. Work upstream of IGF-1 by stimulating pituitary GH release or mimicking ghrelin. The resulting GH pulse triggers hepatic IGF-1 secretion within 2–4 hours, which then undergoes normal IGFBP binding and tissue distribution. This creates a pulsatile IGF-1 profile that mirrors physiological patterns: peak levels 3–6 hours post-dose, gradual decline as IGFBPs sequester circulating IGF-1, and return to baseline within 12–18 hours.
- IGF-1 LR3 bypasses the entire GH axis. It binds the IGF-1 receptor directly, independent of GH secretion, GHRH tone, or somatostatin inhibition. Research models use secretagogues when the goal is to study the complete GH/IGF-1 axis. Pulsatility, feedback loops, hepatic conversion, IGFBP dynamics. IGF-1 LR3 is selected when the goal is isolated receptor activation without upstream endocrine involvement.
- The distinction matters for experimental design. Secretagogues produce variable IGF-1 responses depending on pituitary reserve, hepatic function, and circadian GH rhythmicity. A 25mg dose of MK-677 might elevate IGF-1 by 60% in one model and 35% in another based on baseline GH tone. IGF-1 LR3 delivers consistent receptor saturation independent of those variables because it acts at the final common pathway. Our experience reviewing peptide protocols shows that researchers choose secretagogues for systemic metabolic studies and IGF-1 LR3 for tissue-specific receptor saturation experiments. The tools aren't interchangeable.